about
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobac...
Read More
102.87
0.98
(0.96%)
4.0M
XNAS Volume
XNAS 15 Jul, 2025 4:00 PM (EDT)
Low Financial Strength
Expensive Valuation
Technically Moderately Bullish
Momentum Trap
These stocks are with a bad quality and poor financial score ranging from medium to expensive valuation. Rising technical aspects may attract investors, but, weak financials cannot be overlooked.
View Similar
Embed DVM
Insmed Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..